Cargando…
Pirfenidone: A novel hypothetical treatment for COVID-19
Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibroti...
Autor principal: | Seifirad, Soroush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297676/ https://www.ncbi.nlm.nih.gov/pubmed/32575019 http://dx.doi.org/10.1016/j.mehy.2020.110005 |
Ejemplares similares
-
Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
por: Seifirad, Soroush, et al.
Publicado: (2021) -
Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021) -
An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium
por: Seifirad, Soroush
Publicado: (2014) -
Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
por: Zhou, Xianglin, et al.
Publicado: (2022) -
Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)